Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-119) and T helper epitopes of tetanus toxoid

W. A. Keitel, K. E. Kester, R. L. Atmar, A. Clinton White, N. H. Bond, C. A. Holland, U. Krzych, D. R. Palmer, A. Egan, C. Diggs, W. R. Ballou, B. F. Hall, D. Kaslow

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

The safety and immunogenicity of 2 yeast-derived, blood-stage malaria vaccines were evaluated in a phase l trial. Healthy adults were given 2 or 3 doses of alum-adsorbed vaccine containing the 19 kDa carboxy-terminal fragment of the merozoite surface protein-1 (MSP-119) derived from the 3D7 or the FVO strain of Plasmodium falciparum fused to tetanus toxoid T-helper epitopes P30 and P2. The first 2 doses of MSP-119 were well tolerated. Hypersensitivity reactions occurred in 3 subjects after the third dose of MSP-119, including bilateral injection site reactions in 2 (one with generalized skin rash), and probable histamine-associated hypotension in 1. Serum antibody responses to MSP-119 occurred in 5/16, 9/16 and 0/8 subjects given 20 μg of MSP-119, 200 μg of MSP-119, and control vaccines (hepatitis B or Td), respectively. Both MSP-119 vaccines were immunogenic in humans, but changes in formulation will be necessary to improve safety and immunogenicity profiles. Copyright (C) 1999 Elsevier Science Ltd.

Original languageEnglish (US)
Pages (from-to)531-539
Number of pages9
JournalVaccine
Volume18
Issue number5-6
DOIs
StatePublished - Oct 14 1999
Externally publishedYes

Fingerprint

Merozoite Surface Protein 1
Tetanus Toxoid
Synthetic Vaccines
merozoites
toxoids
tetanus
surface proteins
Plasmodium falciparum
recombinant vaccines
epitopes
Epitopes
Vaccines
vaccines
Malaria Vaccines
Safety
Hepatitis B Vaccines
dosage
Exanthema
immune response
Hypotension

Keywords

  • Malaria vaccines
  • Merozoite surface protein
  • Plasmodium falciparum

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-119) and T helper epitopes of tetanus toxoid. / Keitel, W. A.; Kester, K. E.; Atmar, R. L.; White, A. Clinton; Bond, N. H.; Holland, C. A.; Krzych, U.; Palmer, D. R.; Egan, A.; Diggs, C.; Ballou, W. R.; Hall, B. F.; Kaslow, D.

In: Vaccine, Vol. 18, No. 5-6, 14.10.1999, p. 531-539.

Research output: Contribution to journalArticle

Keitel, WA, Kester, KE, Atmar, RL, White, AC, Bond, NH, Holland, CA, Krzych, U, Palmer, DR, Egan, A, Diggs, C, Ballou, WR, Hall, BF & Kaslow, D 1999, 'Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-119) and T helper epitopes of tetanus toxoid', Vaccine, vol. 18, no. 5-6, pp. 531-539. https://doi.org/10.1016/S0264-410X(99)00221-2
Keitel, W. A. ; Kester, K. E. ; Atmar, R. L. ; White, A. Clinton ; Bond, N. H. ; Holland, C. A. ; Krzych, U. ; Palmer, D. R. ; Egan, A. ; Diggs, C. ; Ballou, W. R. ; Hall, B. F. ; Kaslow, D. / Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-119) and T helper epitopes of tetanus toxoid. In: Vaccine. 1999 ; Vol. 18, No. 5-6. pp. 531-539.
@article{67a3a0864dd14b7a957c1fc18194e874,
title = "Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-119) and T helper epitopes of tetanus toxoid",
abstract = "The safety and immunogenicity of 2 yeast-derived, blood-stage malaria vaccines were evaluated in a phase l trial. Healthy adults were given 2 or 3 doses of alum-adsorbed vaccine containing the 19 kDa carboxy-terminal fragment of the merozoite surface protein-1 (MSP-119) derived from the 3D7 or the FVO strain of Plasmodium falciparum fused to tetanus toxoid T-helper epitopes P30 and P2. The first 2 doses of MSP-119 were well tolerated. Hypersensitivity reactions occurred in 3 subjects after the third dose of MSP-119, including bilateral injection site reactions in 2 (one with generalized skin rash), and probable histamine-associated hypotension in 1. Serum antibody responses to MSP-119 occurred in 5/16, 9/16 and 0/8 subjects given 20 μg of MSP-119, 200 μg of MSP-119, and control vaccines (hepatitis B or Td), respectively. Both MSP-119 vaccines were immunogenic in humans, but changes in formulation will be necessary to improve safety and immunogenicity profiles. Copyright (C) 1999 Elsevier Science Ltd.",
keywords = "Malaria vaccines, Merozoite surface protein, Plasmodium falciparum",
author = "Keitel, {W. A.} and Kester, {K. E.} and Atmar, {R. L.} and White, {A. Clinton} and Bond, {N. H.} and Holland, {C. A.} and U. Krzych and Palmer, {D. R.} and A. Egan and C. Diggs and Ballou, {W. R.} and Hall, {B. F.} and D. Kaslow",
year = "1999",
month = "10",
day = "14",
doi = "10.1016/S0264-410X(99)00221-2",
language = "English (US)",
volume = "18",
pages = "531--539",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "5-6",

}

TY - JOUR

T1 - Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-119) and T helper epitopes of tetanus toxoid

AU - Keitel, W. A.

AU - Kester, K. E.

AU - Atmar, R. L.

AU - White, A. Clinton

AU - Bond, N. H.

AU - Holland, C. A.

AU - Krzych, U.

AU - Palmer, D. R.

AU - Egan, A.

AU - Diggs, C.

AU - Ballou, W. R.

AU - Hall, B. F.

AU - Kaslow, D.

PY - 1999/10/14

Y1 - 1999/10/14

N2 - The safety and immunogenicity of 2 yeast-derived, blood-stage malaria vaccines were evaluated in a phase l trial. Healthy adults were given 2 or 3 doses of alum-adsorbed vaccine containing the 19 kDa carboxy-terminal fragment of the merozoite surface protein-1 (MSP-119) derived from the 3D7 or the FVO strain of Plasmodium falciparum fused to tetanus toxoid T-helper epitopes P30 and P2. The first 2 doses of MSP-119 were well tolerated. Hypersensitivity reactions occurred in 3 subjects after the third dose of MSP-119, including bilateral injection site reactions in 2 (one with generalized skin rash), and probable histamine-associated hypotension in 1. Serum antibody responses to MSP-119 occurred in 5/16, 9/16 and 0/8 subjects given 20 μg of MSP-119, 200 μg of MSP-119, and control vaccines (hepatitis B or Td), respectively. Both MSP-119 vaccines were immunogenic in humans, but changes in formulation will be necessary to improve safety and immunogenicity profiles. Copyright (C) 1999 Elsevier Science Ltd.

AB - The safety and immunogenicity of 2 yeast-derived, blood-stage malaria vaccines were evaluated in a phase l trial. Healthy adults were given 2 or 3 doses of alum-adsorbed vaccine containing the 19 kDa carboxy-terminal fragment of the merozoite surface protein-1 (MSP-119) derived from the 3D7 or the FVO strain of Plasmodium falciparum fused to tetanus toxoid T-helper epitopes P30 and P2. The first 2 doses of MSP-119 were well tolerated. Hypersensitivity reactions occurred in 3 subjects after the third dose of MSP-119, including bilateral injection site reactions in 2 (one with generalized skin rash), and probable histamine-associated hypotension in 1. Serum antibody responses to MSP-119 occurred in 5/16, 9/16 and 0/8 subjects given 20 μg of MSP-119, 200 μg of MSP-119, and control vaccines (hepatitis B or Td), respectively. Both MSP-119 vaccines were immunogenic in humans, but changes in formulation will be necessary to improve safety and immunogenicity profiles. Copyright (C) 1999 Elsevier Science Ltd.

KW - Malaria vaccines

KW - Merozoite surface protein

KW - Plasmodium falciparum

UR - http://www.scopus.com/inward/record.url?scp=0032866084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032866084&partnerID=8YFLogxK

U2 - 10.1016/S0264-410X(99)00221-2

DO - 10.1016/S0264-410X(99)00221-2

M3 - Article

C2 - 10519944

AN - SCOPUS:0032866084

VL - 18

SP - 531

EP - 539

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 5-6

ER -